Prospective randomised comparison of granulocyte colony-stimulating factor (G-CSF) (filgrastim) secondary prophylaxis versus conservative management of chemotherapy-induced neutropenia to maintain dose intensity in chemotherapy for breast cancer
Completed
- Conditions
- BreastCancer
- Registration Number
- ISRCTN89698860
- Lead Sponsor
- Anglo Celtic Cooperative Oncology Group (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 400
Inclusion Criteria
1. 18 years or older
2. Histologically confirmed invasive breast cancer
3. No concomitant malignancy
4. No prior chemotherapy (apart from the current regimen)
5. Previous neutropenic event on iv chemotherapy and considered of suitable risk and fitness to continue chemotherapy
6. Written informed consent
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration